BDBM107704 US11426393, Compound Table XV.11::US8598210, 119::US8598210, Table XV, 10::US8598210, Table XV, 11::US8722895, 10: {[5-(3-Chlorophenyl)-3-hydroxypyridine-2- carbonyl]amino}-acetic acid trifluoroacetic acid salt::US8722895, 11: {[5-(3-Chlorophenyl)-3-hydroxypyridine-2- carbonyl]amino}-acetic acid::US9598370, Example 00136::USRE47437, Example {[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid

SMILES OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1

InChI Key InChIKey=JGRXMPYUTJLTKT-UHFFFAOYSA-N

Data  1 KI  22 IC50  4 EC50

PDB links: 3 PDB IDs match this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 27 hits for monomerid = 107704   

TargetProlyl 4-hydroxylase(PBCV-1)
University of Oxford

Curated by ChEMBL
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataKi:  280nMAssay Description:Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-in...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha inhibitor(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  2.90E+4nMAssay Description:Inhibition of FIH (unknown origin) by solid-phase extraction coupled to MS based assayMore data for this Ligand-Target Pair
TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataEC50:  7.60E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  410nMT: 25°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.10E+3nMT: 25°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMT: 25°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  410nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataEC50:  7.60E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  410nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataEC50:  7.60E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.37E+4nMAssay Description:Inhibition of HIF-PHD2 (unknown origin) expressed in insect Hi5 cells using peptide as substrateMore data for this Ligand-Target Pair
TargetProlyl 3-hydroxylase OGFOD1(Human)
University of Oxford

Curated by ChEMBL
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  29nMAssay Description:Inhibition of recombinant human PHD2 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-asc...More data for this Ligand-Target Pair
TargetProlyl 4-hydroxylase(PBCV-1)
University of Oxford

Curated by ChEMBL
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-in...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha inhibitor(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  2.90E+4nMAssay Description:Inhibition of recombinant human FIH using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-asco...More data for this Ligand-Target Pair
TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  410nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataEC50:  7.60E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  29nMAssay Description:Inhibition of N-terminal His tagged PHD2 (181 to 426 residues) (unknown origin) measured by MALDI-TOF MS analysisMore data for this Ligand-Target Pair
TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  410nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair